{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease",
      "description": "A small assortment of academic articles describing quantitatively described interactions between the MAPT (Tau) protein and small molecules",
      "version": "0.1.0",
      "authors": "Charles Tapley Hoyt"
    },
    "namespace_url": {
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/8259206e39a3578e64bbce1cd0b80e6cfb4da65b/export/hbp.belns",
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/9a77ac1a02863bc48b04bab7e8fb0c1d1cec4dd0/external/chebi.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/9a77ac1a02863bc48b04bab7e8fb0c1d1cec4dd0/external/go.belns"
    },
    "namespace_pattern": {},
    "namespaces_uncached": [],
    "annotation_url": {},
    "annotation_pattern": {
      "MeasurementValue": ".*",
      "MeasurementRangeLower": ".*",
      "MeasurementRangeUpper": ".*",
      "Page": ".*",
      "Figure": ".*",
      "ArticleCompoundNumber": ".*"
    },
    "annotation_list": {
      "MeasurementType": [
        "IC50"
      ],
      "MeasurementUnits": [
        "μM"
      ],
      "MeasurementRelation": [
        "=",
        "~"
      ]
    },
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/bulic2012.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "10642",
      "id": "03a1ca7d8da603094ff9ecf327c24de8067ca96dc0ef6b31102cfbe2b8bc625f1ed80a74eabb6c60189cdffbf752dc909fa41c4b3b43e116547043760121c8d7"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "112284",
      "id": "2383c791b89eaa1b20e4bec16a7f8ba79f116c892e711cb8bbcb73ee1a42c9b89ff745a346fd67be3e34540dcda9d1fea05c3bb5f9d0b012f342d8b6897374c5"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "1457",
      "id": "f6001f6210fa2474cd8bfe9766b3658e915a2ad8d82debb1214d91ed2aece377ff30c7f7ea29c203a9b9d4d024d9f625292e8283939c34a84f52c2243d785888"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "18152",
      "id": "2b0c5802f948265c6627fdd01cf1d016297a0812b4528a184e6435ed5701870be7016b89d8b3f326d2a54e99dbcffa997255e4dcd3db4f59d8048b77ccda47c8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "22580",
      "id": "150eb8f16ffda43dfa27f2b9287b57321752a9f06bbdf60d176ce81abbcab30f2429598968ad5dc1d93b4a8d6cbff3379cb63e75305bf4214aaf889e37f60d8a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "3441",
      "id": "33718cd54990be71dd45f60a78e8872f036cc058549e6ef1b16eeaa420b1143129fa1db096fa6c61b06f45235b356edbdf2a23924bd63e1197cef52ad8a9c936"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "3647",
      "id": "3811308d2d2c98a77d7eeaf63fe8a2d843401c38ef763021c63f6ca32601aa200ccb84ff18af29ef0aab71a306f82fe6b093fd955b2dbc9be6fd6b557c69cce8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "44932",
      "id": "cc9444fc4d98eef6538d8814b9c0cfb4fc1ecc7dc01afae658ab6dc3afdbf51be2e4753f7cb2c36b322576c7d24daffacc93c27b5219c727a556b8ab47a8d5cd"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "4806",
      "id": "15a0a316e15040d0368bc57beb56dce0a981ba71706f4831396e2b47794b05b7561117513f9fea9068b0866e51cdfc1f910be227f460697b6ff35d6515109c8a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "6710",
      "id": "7526fc8ffd1fa031fbd09ea85655b4fbf507d04ae64ca5f4809d884a9dcf63987b6e23f37e560b42e33a45a82cea15c25585f6a7d635bdc3d9163d4c453ca397"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "6872",
      "id": "db35458fdf2ccd61b0e147e8e8b3067051fc9c60269c00ee0c6151c30128488b325d8986c2d8c072fbed4439af90ba24e5e231d3e0888a77b4ea9b4706416417"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "74460",
      "id": "dbab548db21cbc88b1da0c63c5afbbfc3d6509f21e8117d185e8f90a0d54e6cb07034f816c879300c4aa7d30e41c0e73c878eb20ba7b9c87fe1dde6c871ed11f"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "76034",
      "id": "96c3dc259554904457cd50b9cde9568bb354e50672c6fdd6af581ab9e4cd4c108b2290c4d2621df5b17c68a4e6ea61adf4d89cbba40c56195d78c1639f969817"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "8028",
      "id": "029d75b7582d24d76d8554826ac173a0b417f54964405cc85f06dc9a520f07fdc39ed835753440e5ea62d64adfd074fd154eb717a75f1801a65815f3877fafd6"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "87637",
      "id": "61962819e69554d965b6811f6aeb27bb58e1c1046b6af7a4a47d795d6359bec4fe09cbf743e4d0a65192e2825c92deb504b7d70278326f4cfc73cdc51027a2d1"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "90",
      "id": "bd576a55d1ad28c0af16415d17e6473902be031b0a935e9a33ca386a41becaf29307cfc92c474506d3cb3745a1dc727406d3fc950416bf75fe0987217edfeba0"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "GO:0097418",
      "id": "fdc92577af09f60fa3b05c796780c4a6131db9f614468c7a6c234636af16b78631a2cc89aa49f145a715e3e445cfdcc55d2551df3ae9bc56f3c179e453dba4bc"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "HBP00006",
      "id": "9b1d89d922db273dc91b96b20d332236f065e4b4c3d625fb7f3bb266d7559cfc3e316823ea339ea3dd3e4905c14ea1a3af7b7cf5551ffa2696a1fb7c2a6c5739"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "HBP00018",
      "id": "02687c6eeb46ccbcbec50069a9cfb1fa68f909b6e2561113168056b67bb0bf2ba792947c01184f651a07fba88c5a3be36308763e517d8df555da97bc1e2156aa"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "HBP00019",
      "id": "0fd16ef7aedc1d53480aa66f4b4948746fa3468e07e02698a76eb2f3461f493798d6c5780c1435aea482be6987939df159ca7d8da569f1868e98e10711d761c8"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "HBP00020",
      "id": "ecaefbc74130ab17cb01edf5a5fa699ab2685e7c68ef585120482ed8a1d2f0a965cabdf1d1a0266f7a9df2930e6e11c99b88cd26856d6dcebfed0eeed8895b65"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "HBP00021",
      "id": "5b2e4411ce5e23fed39aa07e91a0666cf561a3931bf28b9053b6962ee53a61bbe535ec6080c82d4da17f1cdab42575082b47bf3905b788932de9032852b0e8f1"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "76034",
          "id": "96c3dc259554904457cd50b9cde9568bb354e50672c6fdd6af581ab9e4cd4c108b2290c4d2621df5b17c68a4e6ea61adf4d89cbba40c56195d78c1639f969817"
        },
        {
          "function": "Abundance",
          "namespace": "GO",
          "name": "GO:0097418",
          "id": "fdc92577af09f60fa3b05c796780c4a6131db9f614468c7a6c234636af16b78631a2cc89aa49f145a715e3e445cfdcc55d2551df3ae9bc56f3c179e453dba4bc"
        }
      ],
      "id": "2b69c9396e37e405b017a739ecbe1e7805e5571f083912d1a673cf01fd341851e73638077eb8622e79ec1698fbdcf3099449e015d9f788810628e6f10329381b"
    }
  ],
  "links": [
    {
      "line": 57,
      "relation": "decreases",
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "D": true
        },
        "Figure": {
          "4": true
        },
        "ArticleCompoundNumber": {
          "1": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementRangeLower": {
          "1.9": true
        },
        "MeasurementRangeUpper": {
          "31": true
        }
      },
      "source": 10,
      "target": 17,
      "key": "b22bdb42bb4aa2fa6fec80b22677f9e1efa31f4da13f7a9434988030374f8b30196d99a581b7bffe149e3e18e109375fb5ac73f25695d096b3d460ac572d3e66"
    },
    {
      "line": 65,
      "relation": "causesNoChange",
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "D": true
        },
        "Figure": {
          "4": true
        },
        "ArticleCompoundNumber": {
          "3": true
        }
      },
      "source": 13,
      "target": 17,
      "key": "5ee410834aba51ce2320c162e11588548b04779fee81fd0cf69f78c4f439f605b1227b23e2a9ed313d96dba8e885437db18f4e5830307ce77722025e58a52743"
    },
    {
      "line": 71,
      "relation": "causesNoChange",
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "D": true
        },
        "Figure": {
          "4": true
        },
        "ArticleCompoundNumber": {
          "4": true
        }
      },
      "source": 7,
      "target": 17,
      "key": "8d9a332d60a3dd0254dd58dba51282d5f2efa09c948ea72a06dbcbdb8aacc6415ae46e0481c29f904ff95ce2819bd9165fc6496d158b604dce23f49cdc6160ff"
    },
    {
      "line": 77,
      "relation": "causesNoChange",
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "D": true
        },
        "Figure": {
          "4": true
        },
        "ArticleCompoundNumber": {
          "5": true
        }
      },
      "source": 6,
      "target": 17,
      "key": "fbe084d99d55f3f16b70cc7d86786a0e118c1a36acc09f44156249f9a3a09423d293fa344287a76c4a8f0b6f76b9a9c29156871004ba9b72587b2e9c77b4f0bf"
    },
    {
      "line": 87,
      "relation": "decreases",
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "D": true
        },
        "Figure": {
          "4": true
        },
        "ArticleCompoundNumber": {
          "6": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementValue": {
          "2.6": true
        }
      },
      "source": 14,
      "target": 17,
      "key": "df2bd89566bfd48813de657c89bb029088cf1931e9103ef24c9d18fb270facd2713c15994e279033a0a5db37751415b47a412c3572fe951e0abd26d10ccb32c5"
    },
    {
      "line": 97,
      "relation": "decreases",
      "evidence": "Redox cycling of methylene blue and TAGI potencies. Upper panel (black): Reduced leuco form 2 and structural overlap with inactive phenothiazines 3, 4, and 5. Lower panel (blue): Structural overlap between oxidized form 1 and azure A (6), reduced anthraquinone, 8, and 9, showing the extended π-conjugated system (ND: not determined).",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "D": true
        },
        "Figure": {
          "4": true
        },
        "ArticleCompoundNumber": {
          "7": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementRelation": {
          "~": true
        },
        "MeasurementValue": {
          "2": true
        }
      },
      "source": 4,
      "target": 17,
      "key": "54324e2fb050b0ba67ecd054e408119d22caecc7292fdec3f764d6080d73fb4be8b963463188d87a15f8ebb3137aedb5654958533e788d3185df3931ff83ca2b"
    },
    {
      "line": 115,
      "relation": "decreases",
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "F": true
        },
        "Figure": {
          "6": true
        },
        "ArticleCompoundNumber": {
          "10": true
        }
      },
      "source": 2,
      "target": 18,
      "key": "f24bf67f60c9b1bdb206e545f700f5be3f946e2e607320638d8ce7d920a8fb5b9605df7af78adb81fd372ca0a59c7470cf669da42c1e27f01ab770adbbf7990c"
    },
    {
      "line": 121,
      "relation": "decreases",
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "F": true
        },
        "Figure": {
          "6": true
        },
        "ArticleCompoundNumber": {
          "11": true
        }
      },
      "source": 0,
      "target": 18,
      "key": "c7b21e9f2e4e7f443e449bf30e217df113aba5c86311d07f6534098670404152eebb3ae3bc826c9c9e9881803bc16afab46ad7e08cb4c9074d3a011820ee9265"
    },
    {
      "line": 127,
      "relation": "decreases",
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "F": true
        },
        "Figure": {
          "6": true
        },
        "ArticleCompoundNumber": {
          "12": true
        }
      },
      "source": 8,
      "target": 18,
      "key": "7a96e4be709fddde172f6fbdd14a25c604889dcaccf678bf3c4313adcc6b2322414a47b6c3d875cc1681f0207c838a4fcebebc0368d2fb878e2aef0e7c4a2af7"
    },
    {
      "line": 163,
      "relation": "decreases",
      "evidence": "Pyrogallol generic substitution pattern commonly found in multiple polyphenolic Tau aggregation inhibitors such as 12 and 19. Note the structural overlap with the inactive pyrocatechol-substituted epicatechin",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "H": true
        },
        "Figure": {
          "8": true
        },
        "ArticleCompoundNumber": {
          "12": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementValue": {
          "1.8": true
        }
      },
      "source": 8,
      "target": 17,
      "key": "94dc6ebed79ca89931a20909539c6bee75d6a04a124a0c02010483881b6ec2f12425488cc09e22da45c550802f661b95ea31605c409016bfecf28b44f3e54802"
    },
    {
      "line": 133,
      "relation": "decreases",
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "F": true
        },
        "Figure": {
          "6": true
        },
        "ArticleCompoundNumber": {
          "13": true
        }
      },
      "source": 11,
      "target": 18,
      "key": "476b624bfde58fe9a9b057e8fd0393c7c20d18f8ac8115eea416f9d1b5c3897a691314dac4d8af54c441de9590996daac7b0aac0a2d5ca39a21484fa583810e1"
    },
    {
      "line": 139,
      "relation": "decreases",
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "F": true
        },
        "Figure": {
          "6": true
        },
        "ArticleCompoundNumber": {
          "14": true
        }
      },
      "source": 21,
      "target": 18,
      "key": "94cab5fa33127a9ff32a5275fc7fa10e35086f2966f2dc06b518b23385abfbc8523a72bb6dfce3a878f1211ce562f90c9dc669b82570fb3557b8bba2170ba1ba"
    },
    {
      "line": 145,
      "relation": "decreases",
      "evidence": "Structures of Aβ-aggregation inhibitors evaluated in current or past clinical trials.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "F": true
        },
        "Figure": {
          "6": true
        },
        "ArticleCompoundNumber": {
          "14": true
        }
      },
      "source": 19,
      "target": 18,
      "key": "817b7fe4a0be1bb8d43b1fd6710921484fb3b68475512949fe3b8cae8833a78f55721656cfa67ec330641ee42774b4aea61a2ea663b39a71372ca02e470bbb2e"
    },
    {
      "line": 169,
      "relation": "causesNoChange",
      "evidence": "Pyrogallol generic substitution pattern commonly found in multiple polyphenolic Tau aggregation inhibitors such as 12 and 19. Note the structural overlap with the inactive pyrocatechol-substituted epicatechin",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "H": true
        },
        "Figure": {
          "8": true
        },
        "ArticleCompoundNumber": {
          "18": true
        }
      },
      "source": 15,
      "target": 17,
      "key": "00b008d71db3a48af48a8c4f187e911389babd3659a279c374d2c9daf19fad251a16a795bd3b6a28621b3fe580f0fdd41053d26929ce8ba1ddeaa0d4f0979eec"
    },
    {
      "line": 179,
      "relation": "decreases",
      "evidence": "Pyrogallol generic substitution pattern commonly found in multiple polyphenolic Tau aggregation inhibitors such as 12 and 19. Note the structural overlap with the inactive pyrocatechol-substituted epicatechin",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "H": true
        },
        "Figure": {
          "8": true
        },
        "ArticleCompoundNumber": {
          "19": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementValue": {
          "1.2": true
        }
      },
      "source": 3,
      "target": 17,
      "key": "5cd4c79441d1b633bbd0d96af3ffed42767c778b596960fe1423c1c03ed31fc2771c62fe00e37a361223d04aa6c7de65568e1e2639534a122680b847aba4224b"
    },
    {
      "line": 219,
      "relation": "decreases",
      "evidence": "Representative examples of N-phenylamine Tau aggregation inhibitors and structural overlap with the Aβ40 aggregation inhibitor 33 or the nonsteroidal anti-inflammatory drug 34.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "K": true
        },
        "Figure": {
          "12": true
        },
        "ArticleCompoundNumber": {
          "33": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementValue": {
          "30": true
        }
      },
      "source": 5,
      "target": 18,
      "key": "dc48a6694a362e33fb9cbfaef242cced4bf2dd99d37b6aba81a38006b4e0e413fc296118996584cabf9874816d3e05c35811d6ef52b2e974a0327fa159062fc1"
    },
    {
      "line": 222,
      "relation": "decreases",
      "evidence": "Representative examples of N-phenylamine Tau aggregation inhibitors and structural overlap with the Aβ40 aggregation inhibitor 33 or the nonsteroidal anti-inflammatory drug 34.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "K": true
        },
        "Figure": {
          "12": true
        },
        "ArticleCompoundNumber": {
          "33": true
        }
      },
      "source": 5,
      "target": 17,
      "key": "6173ee6c8933961ae5f48a9c6aefc1a4cd368b68099acfcddbc5b00ab88d42b2b3a00bf86a08e92d0b38afb1d2d5090b4262d8d35278c3d79215c20c912b6f6e"
    },
    {
      "line": 228,
      "relation": "decreases",
      "evidence": "Representative examples of N-phenylamine Tau aggregation inhibitors and structural overlap with the Aβ40 aggregation inhibitor 33 or the nonsteroidal anti-inflammatory drug 34.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "K": true
        },
        "Figure": {
          "12": true
        },
        "ArticleCompoundNumber": {
          "34": true
        }
      },
      "source": 9,
      "target": 17,
      "key": "a1c78f5fb14c592461ca62b6eb5994fce635ac906939fae2e58910ed205a97f7e5694e7d475e38259179a999b6170b6c18975481c9ce0b5ecd820ac06682b720"
    },
    {
      "line": 229,
      "relation": "decreases",
      "evidence": "Representative examples of N-phenylamine Tau aggregation inhibitors and structural overlap with the Aβ40 aggregation inhibitor 33 or the nonsteroidal anti-inflammatory drug 34.",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "K": true
        },
        "Figure": {
          "12": true
        },
        "ArticleCompoundNumber": {
          "34": true
        }
      },
      "source": 9,
      "target": 18,
      "key": "350f90c6309cba5741020c8aea4d6e8e22a65f11837f1c466255118875cd5e59a684ca96784f9b4f1fee2cb0c6280705ed9ae1486f71f83ed4cd5325e7bf138b"
    },
    {
      "relation": "hasComponent",
      "source": 22,
      "target": 12,
      "key": "28b28667c20344194dc827e3ba5f1ea5cc88530ea58db0a30c262cd4c51b4a25397ad027b715e077e80d7efdc0ea3883a1b5c053c5551642d65201847f6fb0a8"
    },
    {
      "relation": "hasComponent",
      "source": 22,
      "target": 16,
      "key": "ee253cf9a6ae23ef4a4806c95ee6ea4ee3dcc3d0400e590b81eff4b5ea39f68f831cc06c05014454f6e19cbcc9b628df5e1cd6e46cab7a8b25a4e86b63764a5e"
    },
    {
      "line": 272,
      "relation": "decreases",
      "evidence": "Aminothienopyridazines (APTZs) Tau aggregation inhibitors (B/P: blood to plasma ratio).",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "L": true
        },
        "Figure": {
          "14": true
        },
        "ArticleCompoundNumber": {
          "41": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementValue": {
          "5.1": true
        }
      },
      "source": 1,
      "target": 17,
      "key": "87aeb1b8b15223abab4315a532b23a7403e969ce89f33270630015a8b749336500591c0e57578b21f7e7b1581bc30e4a31679fa444aadfba364f4d6a96a2c53a"
    },
    {
      "line": 282,
      "relation": "decreases",
      "evidence": "Aminothienopyridazines (APTZs) Tau aggregation inhibitors (B/P: blood to plasma ratio).",
      "citation": {
        "type": "PubMed",
        "reference": "23484434"
      },
      "annotations": {
        "Page": {
          "L": true
        },
        "Figure": {
          "14": true
        },
        "ArticleCompoundNumber": {
          "41": true
        },
        "MeasurementType": {
          "IC50": true
        },
        "MeasurementUnits": {
          "μM": true
        },
        "MeasurementRelation": {
          "=": true
        },
        "MeasurementValue": {
          "6.3": true
        }
      },
      "source": 20,
      "target": 17,
      "key": "c6c3edd4229c17838c1aa06ccd3659dd1a90823b2c70c66c7b0bd140857eae8dc1171b1b53cf9bc14d15919a3079c05e1a62d8c38aada87e1b60777fd60f06b6"
    }
  ]
}